Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / EXEL - Exelixis Cabometyx + Tecentriq late-stage trial fails in advanced kidney cancer

EXEL - Exelixis Cabometyx + Tecentriq late-stage trial fails in advanced kidney cancer

Exelixis Inc.

  • A phase 3 trial evaluating a combination of Exelixis' ( NASDAQ: EXEL ) Cabometyx (cabozantinib) and Roche ( OTCQX:RHHBY ) Genentech unit's Tecentriq (atezolizumab) in locally advanced or metastatic renal cell carcinoma has failed.
  • The CONTACT-03 study was evaluating the combination in patients who were unsuccessful on immune checkpoint inhibitor therapy vs. Cabometyx.
  • The primary endpoint of progression-free survival was not met.
  • Exelixis ( EXEL ) did not provide details on study results, but said they would be presented at a future medical meeting .
  • Read why Seeking Alpha contributor Que Capital rates Exelixis ( EXEL ) a buy.

For further details see:

Exelixis Cabometyx + Tecentriq late-stage trial fails in advanced kidney cancer
Stock Information
Company Name: Exelixis Inc.
Stock Symbol: EXEL
Market: NASDAQ
Website: exelixis.com
Menu
EXEL EXEL Quote EXEL Short EXEL News EXEL Articles EXEL Message Board
Get EXEL Alerts

News, Short Squeeze, Breakout and More Instantly...